Polymyxin B nonapeptide TFA

Polymyxin B nonapeptide TFA is a truncated form of the well-known antibiotic polymyxin B, lacking the fatty acid tail and thus exhibiting distinct physicochemical and biological properties. As a cationic cyclic peptide, it retains the core cyclic structure of its parent compound, but the removal of the N-terminal fatty acyl chain significantly alters its membrane-disruptive potential and toxicity profile. Polymyxin B nonapeptide TFA is typically supplied as a trifluoroacetate salt, enhancing its solubility and stability for laboratory applications. This peptide is highly valued across research disciplines for its ability to selectively interact with bacterial outer membranes, particularly by binding to lipopolysaccharides (LPS), without exerting the strong bactericidal activity associated with full-length polymyxins. Its unique molecular architecture makes it a versatile tool in the study of bacterial membrane biology, antibiotic resistance mechanisms, and endotoxin neutralization strategies.

Antimicrobial resistance research: In the field of antimicrobial resistance, Polymyxin B nonapeptide TFA serves as a critical probe for dissecting the interactions between cationic peptides and Gram-negative bacterial membranes. Unlike its parent compound, it does not kill bacteria outright, allowing researchers to study the initial binding and permeabilization events without confounding bactericidal effects. By employing this nonapeptide, scientists can investigate how alterations in bacterial outer membrane components, such as modifications in LPS, influence susceptibility to polymyxins and related antibiotics. This knowledge is pivotal for the development of next-generation antimicrobial agents and for understanding the molecular underpinnings of resistance.

Endotoxin neutralization: The strong affinity of Polymyxin B nonapeptide TFA for the lipid A moiety of LPS renders it a valuable agent for endotoxin removal and neutralization in biological samples. Its reduced toxicity compared to full-length polymyxin B makes it suitable for use in sensitive in vitro assays, such as those measuring cytokine release or immune cell activation in response to endotoxins. Researchers utilize the nonapeptide to selectively bind and sequester LPS from protein preparations, cell culture media, or other biological fluids, thereby minimizing the risk of endotoxin-induced artifacts in experimental systems.

Membrane biophysics studies: The structural simplicity and defined charge distribution of Polymyxin B nonapeptide TFA make it an excellent model for studying peptide-membrane interactions at the molecular level. In biophysical experiments, such as surface plasmon resonance, isothermal titration calorimetry, or fluorescence spectroscopy, it enables precise quantification of binding affinities and kinetic parameters. Its interactions with synthetic liposomes or bacterial outer membrane vesicles provide insights into the mechanisms by which cationic peptides perturb membrane integrity, aggregate LPS, or modulate membrane fluidity, contributing to a deeper understanding of membrane-active antimicrobial peptides.

Immunology and inflammation research: Researchers investigating host-pathogen interactions and innate immune responses leverage Polymyxin B nonapeptide TFA to modulate LPS-induced signaling pathways. By pre-incubating immune cells or model organisms with the nonapeptide, it is possible to attenuate LPS-triggered inflammatory responses, thereby elucidating the downstream effects of endotoxin exposure. This approach is instrumental in dissecting the molecular mechanisms of LPS recognition, signaling cascade activation, and cytokine production, facilitating the identification of novel targets for anti-inflammatory interventions.

Analytical and diagnostic assay development: The specificity of Polymyxin B nonapeptide TFA for LPS is harnessed in the creation of LPS detection and quantification assays. It is incorporated into biosensors, ELISA formats, or chromatography matrices to selectively capture and measure endotoxin contamination in pharmaceuticals, biological samples, or industrial products. Its use enhances assay sensitivity and selectivity, providing a reliable means to monitor LPS levels and ensure the quality of research reagents and biotechnological products.

Pharmaceutical formulation research: The nonapeptide is also explored in the context of pharmaceutical formulation, where it is used to reduce endotoxin burdens in protein therapeutics and vaccine preparations. By integrating it into purification workflows or as an additive during production, researchers can achieve more effective endotoxin clearance, thereby improving the safety and reliability of biopharmaceuticals. Its application in this area underscores the broader utility of Polymyxin B nonapeptide TFA as a multifunctional reagent in contemporary biomedical research and development.

1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

2. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

3. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

4. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes